AAPL281.74-2.04 (-0.72%) ▼|ABBV254.31+0.96 (+0.38%) ▲|ABT92.71-1.41 (-1.50%) ▼|ACN124.74-4.24 (-3.29%) ▼|ADBE206.43+3.70 (+1.83%) ▲|AMAT694.64+67.80 (+10.82%) ▲|AMD539.49+17.91 (+3.43%) ▲|AMGN360.55+2.22 (+0.62%) ▲|AMT168.67-6.92 (-3.94%) ▼|AMZN240.14+7.45 (+3.20%) ▲|AVGO372.45+7.43 (+2.04%) ▲|AXP340.88+0.52 (+0.15%) ▲|BA214.69-2.56 (-1.18%) ▼|BAC57.88+0.00 (+0.00%) ▲|BKNG182.41+0.95 (+0.52%) ▲|BLK950.17-14.54 (-1.51%) ▼|BMY58.56+1.04 (+1.81%) ▲|BNY143.80+0.24 (+0.17%) ▲|BRK-B496.00-2.66 (-0.53%) ▼|C142.49+0.73 (+0.52%) ▲|CAT1,033.19+35.72 (+3.58%) ▲|CL92.40+0.33 (+0.36%) ▲|CMCSA24.22+1.05 (+4.53%) ▲|COF202.28-1.72 (-0.84%) ▼|COP104.20-1.76 (-1.66%) ▼|COST946.68-5.86 (-0.62%) ▼|CRM157.93-0.44 (-0.28%) ▼|CSCO117.70+3.93 (+3.45%) ▲|CVS103.58-0.76 (-0.73%) ▼|CVX168.47-2.59 (-1.51%) ▼|DE626.63+13.39 (+2.18%) ▲|DHR192.78-3.41 (-1.74%) ▼|DIS98.63-0.16 (-0.16%) ▼|DUK128.33-0.07 (-0.05%) ▼|EMR142.82-0.67 (-0.47%) ▼|FDX325.40+6.87 (+2.16%) ▲|GD348.07+1.36 (+0.39%) ▲|GE373.71+4.71 (+1.28%) ▲|GEV1,102.51+57.34 (+5.49%) ▲|GILD126.33-1.55 (-1.21%) ▼|GM77.34-0.76 (-0.97%) ▼|GOOG351.28+16.59 (+4.96%) ▲|GOOGL353.65+16.26 (+4.82%) ▲|GS1,020.21+0.60 (+0.06%) ▲|HD350.81+1.95 (+0.56%) ▲|HON227.80-15.61 (-6.41%) ▼|IBM278.00+6.37 (+2.35%) ▲|INTC131.72+3.40 (+2.65%) ▲|INTU266.40-1.32 (-0.49%) ▼|ISRG405.97+1.70 (+0.42%) ▲|JNJ258.51+3.85 (+1.51%) ▲|JPM329.39+0.34 (+0.10%) ▲|KO82.65+0.02 (+0.02%) ▲|LIN511.06-8.56 (-1.65%) ▼|LLY1,229.93+21.81 (+1.81%) ▲|LMT502.07-5.33 (-1.05%) ▼|LOW219.65-2.83 (-1.27%) ▼|LRCX410.91+31.82 (+8.39%) ▲|MA509.64+10.62 (+2.13%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.15-0.64 (-1.05%) ▼|MDT80.93-0.05 (-0.06%) ▼|META562.60+12.35 (+2.24%) ▲|MMM162.43-1.58 (-0.96%) ▼|MO74.05+0.26 (+0.35%) ▲|MRK129.38+0.72 (+0.56%) ▲|MS211.72-0.31 (-0.15%) ▼|MSFT368.57-4.40 (-1.18%) ▼|MU1,145.28+12.95 (+1.14%) ▲|NEE88.66+0.10 (+0.11%) ▲|NFLX73.78-0.03 (-0.04%) ▼|NKE41.48+0.73 (+1.79%) ▲|NOW99.97+1.63 (+1.66%) ▲|NVDA194.97+2.44 (+1.27%) ▲|ORCL147.76-0.77 (-0.52%) ▼|PEP138.68-2.71 (-1.92%) ▼|PFE24.37+0.08 (+0.33%) ▲|PG148.45-0.57 (-0.38%) ▼|PLTR115.70+2.77 (+2.45%) ▲|PM182.87+2.10 (+1.16%) ▲|QCOM188.72-0.67 (-0.35%) ▼|RTX187.33-0.66 (-0.35%) ▼|SBUX104.06-0.54 (-0.52%) ▼|SCHW90.55-0.12 (-0.13%) ▼|SO96.75-0.41 (-0.42%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.82-0.90 (-3.96%) ▼|TMO506.42-6.61 (-1.29%) ▼|TMUS173.97-8.71 (-4.77%) ▼|TSLA411.84+32.13 (+8.46%) ▲|TXN285.48+0.06 (+0.02%) ▲|UBER75.50-0.70 (-0.92%) ▼|UNH419.82-8.07 (-1.89%) ▼|UNP272.70+4.35 (+1.62%) ▲|UPS108.01-0.13 (-0.12%) ▼|USB61.28+0.37 (+0.61%) ▲|V341.65+5.42 (+1.61%) ▲|VZ44.10-2.44 (-5.24%) ▼|WFC83.51-0.35 (-0.42%) ▼|WMT114.60-1.09 (-0.94%) ▼|XOM136.06-0.48 (-0.35%) ▼|AAPL281.74-2.04 (-0.72%) ▼|ABBV254.31+0.96 (+0.38%) ▲|ABT92.71-1.41 (-1.50%) ▼|ACN124.74-4.24 (-3.29%) ▼|ADBE206.43+3.70 (+1.83%) ▲|AMAT694.64+67.80 (+10.82%) ▲|AMD539.49+17.91 (+3.43%) ▲|AMGN360.55+2.22 (+0.62%) ▲|AMT168.67-6.92 (-3.94%) ▼|AMZN240.14+7.45 (+3.20%) ▲|AVGO372.45+7.43 (+2.04%) ▲|AXP340.88+0.52 (+0.15%) ▲|BA214.69-2.56 (-1.18%) ▼|BAC57.88+0.00 (+0.00%) ▲|BKNG182.41+0.95 (+0.52%) ▲|BLK950.17-14.54 (-1.51%) ▼|BMY58.56+1.04 (+1.81%) ▲|BNY143.80+0.24 (+0.17%) ▲|BRK-B496.00-2.66 (-0.53%) ▼|C142.49+0.73 (+0.52%) ▲|CAT1,033.19+35.72 (+3.58%) ▲|CL92.40+0.33 (+0.36%) ▲|CMCSA24.22+1.05 (+4.53%) ▲|COF202.28-1.72 (-0.84%) ▼|COP104.20-1.76 (-1.66%) ▼|COST946.68-5.86 (-0.62%) ▼|CRM157.93-0.44 (-0.28%) ▼|CSCO117.70+3.93 (+3.45%) ▲|CVS103.58-0.76 (-0.73%) ▼|CVX168.47-2.59 (-1.51%) ▼|DE626.63+13.39 (+2.18%) ▲|DHR192.78-3.41 (-1.74%) ▼|DIS98.63-0.16 (-0.16%) ▼|DUK128.33-0.07 (-0.05%) ▼|EMR142.82-0.67 (-0.47%) ▼|FDX325.40+6.87 (+2.16%) ▲|GD348.07+1.36 (+0.39%) ▲|GE373.71+4.71 (+1.28%) ▲|GEV1,102.51+57.34 (+5.49%) ▲|GILD126.33-1.55 (-1.21%) ▼|GM77.34-0.76 (-0.97%) ▼|GOOG351.28+16.59 (+4.96%) ▲|GOOGL353.65+16.26 (+4.82%) ▲|GS1,020.21+0.60 (+0.06%) ▲|HD350.81+1.95 (+0.56%) ▲|HON227.80-15.61 (-6.41%) ▼|IBM278.00+6.37 (+2.35%) ▲|INTC131.72+3.40 (+2.65%) ▲|INTU266.40-1.32 (-0.49%) ▼|ISRG405.97+1.70 (+0.42%) ▲|JNJ258.51+3.85 (+1.51%) ▲|JPM329.39+0.34 (+0.10%) ▲|KO82.65+0.02 (+0.02%) ▲|LIN511.06-8.56 (-1.65%) ▼|LLY1,229.93+21.81 (+1.81%) ▲|LMT502.07-5.33 (-1.05%) ▼|LOW219.65-2.83 (-1.27%) ▼|LRCX410.91+31.82 (+8.39%) ▲|MA509.64+10.62 (+2.13%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.15-0.64 (-1.05%) ▼|MDT80.93-0.05 (-0.06%) ▼|META562.60+12.35 (+2.24%) ▲|MMM162.43-1.58 (-0.96%) ▼|MO74.05+0.26 (+0.35%) ▲|MRK129.38+0.72 (+0.56%) ▲|MS211.72-0.31 (-0.15%) ▼|MSFT368.57-4.40 (-1.18%) ▼|MU1,145.28+12.95 (+1.14%) ▲|NEE88.66+0.10 (+0.11%) ▲|NFLX73.78-0.03 (-0.04%) ▼|NKE41.48+0.73 (+1.79%) ▲|NOW99.97+1.63 (+1.66%) ▲|NVDA194.97+2.44 (+1.27%) ▲|ORCL147.76-0.77 (-0.52%) ▼|PEP138.68-2.71 (-1.92%) ▼|PFE24.37+0.08 (+0.33%) ▲|PG148.45-0.57 (-0.38%) ▼|PLTR115.70+2.77 (+2.45%) ▲|PM182.87+2.10 (+1.16%) ▲|QCOM188.72-0.67 (-0.35%) ▼|RTX187.33-0.66 (-0.35%) ▼|SBUX104.06-0.54 (-0.52%) ▼|SCHW90.55-0.12 (-0.13%) ▼|SO96.75-0.41 (-0.42%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.82-0.90 (-3.96%) ▼|TMO506.42-6.61 (-1.29%) ▼|TMUS173.97-8.71 (-4.77%) ▼|TSLA411.84+32.13 (+8.46%) ▲|TXN285.48+0.06 (+0.02%) ▲|UBER75.50-0.70 (-0.92%) ▼|UNH419.82-8.07 (-1.89%) ▼|UNP272.70+4.35 (+1.62%) ▲|UPS108.01-0.13 (-0.12%) ▼|USB61.28+0.37 (+0.61%) ▲|V341.65+5.42 (+1.61%) ▲|VZ44.10-2.44 (-5.24%) ▼|WFC83.51-0.35 (-0.42%) ▼|WMT114.60-1.09 (-0.94%) ▼|XOM136.06-0.48 (-0.35%) ▼|
30.9 C
New York
Monday, June 29, 2026

Tag: program

newssourceFORcompanyinformationcontent1releasesmarket

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...

Chandigarh University holds 8th CU Online Annual Convocation; 363 Students Degrees Awarded

Chandigarh University Sings MoU with Global Consulting Giant PwC to Offer Online MBA Program330 Postgraduate and 33 Undergraduate Degrees Conferred to Online and Distance...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

Bishop’s University researcher co-edits new international volume on language and classroom equity

SHERBROOKE, QC, June 5, 2026 /CNW/ - Every classroom in Canada is already multilingual. A new Bloomsbury column co-edited by Dr. Sunny Man Chu Lau,...

Think Together Awards 2026 Beyond Think Together Scholarships to Ten High School Seniors Across the State

Each recipient received $3,000 to support their future higher education goals.SANTA ANA, Calif., June 5, 2026 /PRNewswire/ -- Think Together, California's largest nonprofit expanded...

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

The City of Hallandale Beach Among 10 Finalists for Climate Protection from US Conference of Mayors; Cloud Receives Small City Award

HALLANDALE BEACH, Fla., June 5, 2026 /PRNewswire/ -- The City of Hallandale Beach was recognized as a finalist in the Small City category of...

HELE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Helen of Troy Limited. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Helen of Troy Limited (HELE) Misled Investors Regarding the Ability of Project Pegasus to Improve Efficiency

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProgram

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers